This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2001 Remove Assay Development Related Topics
Biophysical Assays Compound Screening Screening Hits Fragment Screening Biochemical Assays Computational Chemistry Protein Production Small Molecule Drug Development Virus More Related Topics >
article thumbnail

Roche signs definitive share purchase agreement with long-term partner TIB.

The Pharma Data

SEPTEMBER 8, 2021

TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche`s LightCycler PCR instruments.

Virus 52
Virus Assay Development Disease Research 52
article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

NOVEMBER 1, 2023

We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. In 2001, he joined Astex Pharmaceuticals in Cambridge where he became an expert in fragment-based drug discovery working on diabetes, thrombotic and oncology drug targets.

Fragment Screening 96
Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 15,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024